Jeyakumar SM, Vajreswari A. Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. World J Clin Cases 2021; 9(31): 9333-9349 [PMID: 34877270 DOI: 10.12998/wjcc.v9.i31.9333]
Corresponding Author of This Article
Shanmugam M Jeyakumar, PhD, Senior Scientist, Department of Clinical Pharmacology, ICMR-National Institute for Research in Tuberculosis, No. 1, Sathiyamoorthy Road, Chetpet, Chennai 600031, Tamil Nadu, India. smjkumar@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 6, 2021; 9(31): 9333-9349 Published online Nov 6, 2021. doi: 10.12998/wjcc.v9.i31.9333
Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids
Shanmugam M Jeyakumar, Ayyalasomayajula Vajreswari
Shanmugam M Jeyakumar, Department of Clinical Pharmacology, ICMR-National Institute for Research in Tuberculosis, Chennai 600031, Tamil Nadu, India
Ayyalasomayajula Vajreswari, Department of Biochemistry, National Institute of Nutrition, Hyderabad 500007, Telangana, India
Author contributions: Jeyakumar SM contributed to the conception, summary art drawing, drafting, reviewing and finalization of the manuscript; Vajreswari A critically reviewed the manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest associated with this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shanmugam M Jeyakumar, PhD, Senior Scientist, Department of Clinical Pharmacology, ICMR-National Institute for Research in Tuberculosis, No. 1, Sathiyamoorthy Road, Chetpet, Chennai 600031, Tamil Nadu, India. smjkumar@gmail.com
Received: February 25, 2021 Peer-review started: February 25, 2021 First decision: May 13, 2021 Revised: May 18, 2021 Accepted: August 17, 2021 Article in press: August 17, 2021 Published online: November 6, 2021
Core Tip
Core Tip: Inflammatory cytokine storm seems to pose a risk for patients with non-alcoholic fatty liver disease (NAFLD), as these patients have shown severe coronavirus disease 2019 (COVID-19) compared to those without NAFLD, while, liver injury has been reported to be high among COVID-19 patients. Thus, this bi-directional relationship between NAFLD and COVID-19 may worsen both conditions at least in this subset of patients. Therefore, resolving the inflammatory cytokine storm is an important target, not only in the management of NAFLD but also for COVID-19. In this context, we highlight the pharmacological potential of omega-3 long-chain polyunsaturated fatty acids in the clinical nutrition therapy strategy to resolve inflammatory cytokine storm and its associated tissue injury.
